Bioventix PLC

LSE BVXP.L

Bioventix PLC Price to Sales Ratio (P/S) on January 14, 2025: 12.31

Bioventix PLC Price to Sales Ratio (P/S) is 12.31 on January 14, 2025, a -32.46% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Bioventix PLC 52-week high Price to Sales Ratio (P/S) is 20.82 on February 21, 2024, which is 69.09% above the current Price to Sales Ratio (P/S).
Bioventix PLC 52-week low Price to Sales Ratio (P/S) is 10.08 on December 20, 2024, which is -18.16% below the current Price to Sales Ratio (P/S).
Bioventix PLC average Price to Sales Ratio (P/S) for the last 52 weeks is 16.80.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

LSE: BVXP.L

Bioventix PLC

CEO	Mr. Peter John Harrison MA
IPO Date	April 29, 2014
Location	United Kingdom
Headquarters	27–28 Eastcastle Street
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.

Key trends

Past 5 years